Core Insights - Liquidia Corporation is focused on revolutionizing care for patients with respiratory and vascular diseases through innovative therapies and proprietary technology [2] Company Updates - Liquidia's executive leadership team will provide business updates during fireside chats at two investor conferences in November [1] - The conferences include the 2025 UBS Global Healthcare Conference on November 10 and the Jefferies London Healthcare Conference on November 18 [3] Product Information - Liquidia's first approved product is YUTREPIA™ (treprostinil) inhalation powder, aimed at treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [2] - The company is developing L606, a sustained-release formulation of treprostinil, which is administered twice daily with a next-generation nebulizer [2] - Liquidia also markets generic Treprostinil Injection for the treatment of PAH [2]

Core Viewpoint - Liquidia Corporation is set to report its third quarter 2025 financial results on November 3, 2025, and will host a webcast to discuss these results and provide a corporate update [1]. Group 1: Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases [3]. - The company is currently developing and commercializing products for pulmonary hypertension using its proprietary PRINT Technology [3]. - Liquidia's approved product, YUTREPIA™ (treprostinil) inhalation powder, is used for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD) [3]. - The company is also working on L606, an investigational sustained-release formulation of treprostinil, which is administered twice daily with a next-generation nebulizer [3]. - Additionally, Liquidia markets a generic version of Treprostinil Injection for PAH treatment [3]. Group 2: Webcast Information - The upcoming webcast will be available on Liquidia's website and will be archived for one year [2].

Core Insights - Liquidia Corporation will provide a business update during a fireside chat at the 2025 Wells Fargo Healthcare Conference on September 3, 2025, at 3:45 p.m. ET in Boston [1] - Investors and interested parties can access a webcast of the presentation on Liquidia's website, with an archived version available for at least 30 days post-event [2] Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases [3] - The company's current focus includes the development and commercialization of products for pulmonary hypertension, utilizing its proprietary PRINT Technology [3] - Liquidia's first approved product is YUTREPIA™ (treprostinil) inhalation powder, aimed at treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [3] - The company is also developing L606, a sustained-release formulation of treprostinil, and markets generic Treprostinil Injection for PAH treatment [3]

Core Viewpoint - Liquidia Corporation is set to report its second quarter 2025 financial results on August 12, 2025, and will host a webcast to discuss these results and provide a corporate update [1]. Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases [3]. - The company is engaged in the development and commercialization of products targeting pulmonary hypertension, utilizing its proprietary PRINT Technology [3]. - Liquidia's approved product, YUTREPIA™ (treprostinil) inhalation powder, is designed for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD) [3]. - The company is also working on L606, an investigational sustained-release formulation of treprostinil, which is administered twice daily using a next-generation nebulizer [3]. - Additionally, Liquidia markets a generic version of Treprostinil Injection for PAH treatment [3].

Core Insights - Liquidia Corporation has announced the first commercial shipment of YUTREPIA™ (treprostinil) inhalation powder, following FDA approval on May 23, 2025, for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [1][6] - The company has moved quickly to promote YUTREPIA, with its sales force actively engaging in the market just over a week after FDA approval [2] - A recent court ruling denied United Therapeutics' request for a preliminary injunction against Liquidia, allowing for the full commercial launch of YUTREPIA [2] Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for rare cardiopulmonary diseases, particularly in pulmonary hypertension [9] - The company utilizes its proprietary PRINT technology to create drug formulations, including YUTREPIA, which is designed for enhanced lung deposition [5][9] - Liquidia is also developing L606, a sustained-release formulation of treprostinil, and markets generic Treprostinil Injection for PAH treatment [9] Product Information - YUTREPIA is an inhaled dry-powder formulation of treprostinil, delivered through a user-friendly device, aimed at providing a new therapeutic option for patients with PAH and PH-ILD [5][6] - The product was previously known as LIQ861 during investigational studies and has undergone clinical trials to establish its safety and efficacy [5] Disease Context - PAH is a rare, chronic disease affecting approximately 45,000 patients in the U.S., with no current cure, making symptom management and quality of life improvement critical [3] - PH-ILD encompasses a range of pulmonary diseases affecting over 60,000 patients in the U.S., with associated poor survival rates [4]

Core Insights - Liquidia Corporation will provide a business update during a fireside chat at the 2025 Jefferies Global Healthcare Conference on June 4, 2025 [1] - The event will feature key executives including the CEO, CFO, and Chief Business Officer [1] Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for rare cardiopulmonary diseases [3] - The company is currently developing and commercializing products for pulmonary hypertension using its proprietary PRINT Technology [3] - Liquidia's approved product, YUTREPIA™ (treprostinil) inhalation powder, is used for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD) [3] - The company is also working on L606, an investigational sustained-release formulation of treprostinil, and markets generic Treprostinil Injection for PAH treatment [3]

Core Viewpoint - Liquidia Corporation is facing a patent infringement lawsuit from United Therapeutics Corporation regarding the commercialization of its inhalation powder YUTREPIA™ for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease [1][6] Group 1: Legal Proceedings - United Therapeutics filed a complaint on May 9, 2025, in the U.S. District Court for the Middle District of North Carolina, alleging infringement of U.S. Patent No. 11,357,782 [1] - The lawsuit seeks to prevent Liquidia from commercializing YUTREPIA™ if it receives FDA approval [1][6] - The '782 patent claims the same general method of administering inhaled treprostinil as the previously invalidated '793 patent, which was deemed unpatentable due to prior art [2][6] Group 2: FDA Approval Timeline - The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2025, for the final action on the New Drug Application (NDA) for YUTREPIA [3][6] - United Therapeutics is not seeking an injunction against the FDA to prevent the approval of YUTREPIA [3] Group 3: Company Overview - Liquidia Corporation is focused on developing innovative therapies for patients with rare cardiopulmonary diseases, including pulmonary hypertension [4] - The company’s lead candidate, YUTREPIA™, is an investigational drug utilizing its proprietary PRINT Technology [4]

Core Insights - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases [3] Group 1: Company Overview - Liquidia's current focus includes the development and commercialization of products for pulmonary hypertension and other applications of its proprietary PRINT Technology [3] - The lead candidate, YUTREPIA™ (treprostinil) inhalation powder, is an investigational drug aimed at treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [3] - The company is also developing L606, a sustained-release formulation of treprostinil, and markets generic Treprostinil Injection for PAH treatment [3] Group 2: Upcoming Events - The Chief Financial Officer and Chief Operating Officer, Michael Kaseta, along with Chief Medical Officer, Rajeev Saggar, will provide a business update at the BofA Securities 2025 Health Care Conference on May 13, 2025 [1] - The event will be accessible via a webcast on Liquidia's website, with an archived version available for at least 30 days post-event [2]

Core Viewpoint - Liquidia Corporation has received a favorable ruling from the U.S. District Court, which dismissed United Therapeutics' cross-claim against its New Drug Application (NDA) for YUTREPIA, allowing the company to proceed with its plans for the drug's approval [1][2]. Group 1: Legal Developments - The U.S. District Court dismissed United Therapeutics' cross-claim regarding Liquidia's amendment to its NDA for YUTREPIA, determining that the claim was unripe and lacked standing [1][2]. - United Therapeutics retains the right to appeal the court's decision [2]. Group 2: Product Development and Approval Timeline - The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date for the YUTREPIA NDA on May 24, 2025, following the expiration of regulatory exclusivity on May 23, 2025 [3][6]. - Liquidia aims for YUTREPIA to become the preferred treatment for patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [2][4]. Group 3: Company Overview - Liquidia Corporation focuses on developing innovative therapies for rare cardiopulmonary diseases, with a particular emphasis on pulmonary hypertension [4]. - The company is also working on L606, a sustained-release formulation of treprostinil, and markets a generic version of Treprostinil Injection for PAH treatment [4].

Core Points - Liquidia Corporation will report its first quarter 2025 financial results on May 8, 2025, and will host a webcast at 8:30 a.m. Eastern Time to discuss these results and provide a corporate update [1][2] Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases [3] - The company's primary focus includes the development and commercialization of products for pulmonary hypertension, utilizing its proprietary PRINT Technology [3] - Liquidia's lead candidate is YUTREPIA™ (treprostinil) inhalation powder, aimed at treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [3] - The company is also developing L606, a sustained-release formulation of treprostinil, and markets generic Treprostinil Injection for PAH treatment [3]